Celestica upgraded to a buy at Beacon Securities

A number of new announcements from Celestica (Celestica Stock Quote, Chart TSX, NYSE:CLS) have caused Beacon Securities analyst Gabriel Leung to upgrade his recommendation for the stock, moving from a “Hold” to a “Buy” with an unchanged target price of $13.00. (All figures in US dollars unless noted otherwise.)

Design, manufacturing and supply chain company Celestica announced today, first, the acquisition of light display equipment company Impakt Holdings for $329 million; second, an increase to its 12-18 month operating margin target range to between 3.75 and 4.5 per cent (was between 3.5 per cent and 4.0 per cent); and third, CLS announced that it anticipates full payment of the remaining proceeds (C$122 million) connected to the sale of its Toronto properties.

Leung says the Impakt acquisition and property sale will put Celestica’s net debt at around $190 million, representing just over 0.5x net debt/EBITDA.

“Overall, we view today’s news as being positive for the stock,” Leung said in an update to clients on Wednesday. “Furthermore, with the stock trading at ~8.7x current year P/E versus the group at ~12.7x, combined with CLS’ improving margin profile and stronger book of business, we view the shares as representing a compelling buying opportunity (even factoring potential reviewing uncertainty stemming from the CCS portfolio review).”

Leung currently projects CLS will generate revenue of $6.6-billion and EBITDA of $287-million in fiscal 2018. He says he will update his estimates after the company’s third quarter results, due on October 24.

The analyst’s $13.00 target stems from his 11x calendar 2018 P/E estimate and represents a projected return of 30 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cls
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

1 day ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

1 day ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

1 day ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

2 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

2 days ago